Clinical Trials Logo

Clinical Trial Summary

In this study the investigators explore a pragmatic strategy to increase cognitive screening rates in the community. The investigators will compare the monetary value of different combinations of SCD questionnaires, digital cognitive tests, and blood Alzheimer's Disease (AD) biomarkers to identify the best approach for primary care settings.


Clinical Trial Description

The investigators aim to perform a cluster-randomized study, exploring the effectiveness, efficiency, and acceptability of a pragmatic strategy to increase cognitive screening rates in the community. Participants will be older adults attending social and cultural centers in the greater Munich area. The investigators will compare the monetary value of different combinations of SCD questionnaires, digital cognitive tests, and blood AD biomarkers to identify the best approach for primary care settings. As secondary aims, qualitative interviews will be conducted with general practitioners (GPs) and their patients to explore the acceptability of the proposed new screening strategy; furthermore, the diagnostic utility of an artificial intelligence-based automated analysis of speech will be assessed. The initiative will not only generate novel insights into the optimal approach for large-scale cognitive screening in the general population, but also contribute to an urgently required cultural change in Germany, resulting in a sustainable solution for effective and efficient early recognition and prevention of dementia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06191952
Study type Interventional
Source Ludwig-Maximilians - University of Munich
Contact Dr. Kurz
Phone +4989440055863
Email Psy.Alzheimerzentrum@med.uni-muenchen.de
Status Recruiting
Phase N/A
Start date February 1, 2023
Completion date February 1, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03255720 - Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural Changes N/A
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A
Withdrawn NCT05497817 - A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Terminated NCT03132272 - Immunoadsorption for Treatment of Alzheimer's Disease N/A
Recruiting NCT03275363 - The University of Hong Kong Neurocognitive Disorder Cohort N/A
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Completed NCT02267486 - Exploratory Study for the Validity of QuQu Scale N/A
Active, not recruiting NCT03748303 - Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study Phase 1
Completed NCT03611439 - Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients N/A
Completed NCT04058886 - Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers N/A
Recruiting NCT03584568 - Reappraising Intergeneration Relationships in Dementia Caregiving N/A
Not yet recruiting NCT05113732 - Association of Cognition With Functional Mobility in People With Alzheimer's Disease
Completed NCT03811847 - A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants. Phase 4
Terminated NCT03044249 - A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression Phase 2
Active, not recruiting NCT03661034 - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study) N/A
Completed NCT03718494 - Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)
Completed NCT03602391 - The Senior Companion Program Plus N/A
Completed NCT03548584 - A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type Phase 3